ストックスクリーナーアプリを入手
0.56
3.61%
-0.021
アフターアワーズ：
.56
Evogene Ltd (EVGN) 最新ニュース
Biomica CEO Set to Attend JP Morgan Healthcare Week in San Franc - GuruFocus
Evogene Shares Slip 2.6% as Biotech Stock Tests Key Support Level (EVGN)Wave Extension - newsline.com
Evogene Sets Up $2.9 Million At-the-Market Share Offering With A.G.P. - The Globe and Mail
Evogene enters sales agreement for at-the-market offering of up to $2.93 million - Investing.com Australia
Evogene Ltd. (NASDAQ: EVGN) launches $2.93M ATM program with A.G.P. - Stock Titan
Evogene (EVGN) launches $2.93M at-the-market share offering with A.G.P. - Stock Titan
EVGN Q1 2026 Earnings: Significant EPS Miss Amid Ongoing Operational ChallengesBasic EPS Analysis - newsline.com
Evogene Q1 revenue falls to $0.3 million amid strategic shift - scanx.trade
Full Transcript: Evogene Q1 2026 Earnings Call - Benzinga
Inside Evogene’s AI drug hunt: ChemPass platform hits BIO 2026 stage - Stock Titan
Earnings Call Summary | Evogene(EVGN.US) Q1 2026 Earnings Conference - 富途牛牛
EVGN Stock Price, Quote & Chart | EVOGENE LTD (NASDAQ:EVGN) - ChartMill
Why Did EVGN Shares Drop More Than 14% Today? - Stocktwits
EVGN Q1 2026 Earnings: EPS Misses Estimates Significantly, Stock DeclinesProfit Guidance Range - newsline.com
Evogene completes phase 1 trial of BMC128 cancer treatment By Investing.com - Investing.com South Africa
Evogene: Q1 Earnings Snapshot - AOL.com
Evogene (EVGN) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Evogene says Phase 1 clinical study of BMC128 met primary endpoint - TipRanks
Evogene completes phase 1 trial of BMC128 cancer treatment - Investing.com
Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica - PR Newswire
Evogene Ltd stock (IL0010831684): Shares trade quietly as investors await next catalysts - AD HOC NEWS
Evogene (EVGN) Edges Lower, Testing Key Support at $0.66Dealer Delta - newsline.com
Evogene Ltd (EVGN) Holding Near Support After Modest DeclineFibonacci Arc - The Legal Advocate
EVGN Q1 2026 Earnings: Significant EPS Miss Highlights Operational ChallengesShare Repurchase Impact - The Legal Advocate
Evogene Back Under $1 as Nasdaq Deadline Approaches - Bez Kabli
Evogene (EVGN) Edges Higher: Modest Uptick Amid Support Level TestFactor Crowding - The Legal Advocate
Evogene Ltd (EVGN) Q1 2026 Earnings Call Highlights: Strategic Collaborations Amid Financial ... By GuruFocus - Investing.com Canada
EVGN - Finviz
Evogene (EVGN) Slides 3% as Shares Test Key Support Near $0.66Put Wall - newsline.com
A. G. P. Maintains Evogene(EVGN.US) With Buy Rating, Cuts Target Price to $2.15 - Moomoo
Evogene shares decline after revenue miss despite stronger-than-expected earnings (EVGN) - MSN
Evogene Q1 2026 earnings preview - MSN
Evogene Ltd. (NASDAQ:EVGN) Q1 2026 Earnings Call Transcript - Insider Monkey
Earnings call transcript: Evogene reports Q1 2026 loss, stock rises 1.95% By Investing.com - Investing.com South Africa
Evogene Earnings Call: AI Momentum vs. Cash Strain - The Globe and Mail
Evogene Reports First Quarter 2026 Financial Results - Global Agriculture
Evogene Ltd stock (IL0010831684): Q1 revenue slump highlights high?risk transformation phase - AD HOC NEWS
Evogene stock falls 5% on revenue miss despite earnings beat - Investing.com
Evogene earnings beat by $0.26, revenue fell short of estimates - Investing.com Australia
Evogene Q1 2026 Loss Deepens: -$0.60/Share vs -$0.28 Expected - AlphaStreet
EVGN: Revenue fell sharply and net loss widened as focus shifted to core AI-driven pharma and ag chem - TradingView
EVGN: AI-driven pharma and ag chemical focus advances, but Q1 revenue drops and net loss widens - TradingView
Earnings call transcript: Evogene reports Q1 2026 loss, stock rises 1.95% - Investing.com Canada
Evogene Ltd. Q1 2026 Earnings Call Summary - Yahoo Finance
Evogene Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Evogene reports Q1 results: net loss widens amid revenue decline - grafa.com
Evogene Shares Decline After Revenue Miss Despite Stronger-Than-Expected Earnings (EVGN) - Yahoo Finance
Evogene Ltd reports results for the quarter ended March 31Earnings Summary - TradingView
Evogene Ltd files for offering of 2.45 million ordinary shares by selling shareholder SEC filing - marketscreener.com
Evogene 1Q Loss/Shr 60c >EVGN.TV - Moomoo
Evogene Ltd Files For Offering Of 2.45 Million Ordinary Shares By Selling Shareholder SEC Filing - TradingView
Evogene (NASDAQ: EVGN) registers 2.45M shares for resale, files Q1 2026 results - Stock Titan
Evogene Tightens Focus on AI Small-Molecule Platform as Q1 2026 Revenue Falls - TipRanks
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):